NBI-1117568
Phase 3Small molecule
Neurocrine BiosciencesNBI-1117568 is one of 80 small molecule programs targeting Bipolar I Disorder. It is currently in Phase 3.
2
Indications
6
Total Trials
5
Active Trials
79
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
583 competitors in Schizophrenia
#DrugCompanyPhaseTrials
1NBI-1117568
Neurocrine BiosciencesPhase 3
Celexa
AbbViePreclinical
Inapsine
Alnylam PharmaceuticalsPreclinical
Ozempic
Novo NordiskPreclinical
Resotran
TakedaPreclinical
Depakote
AbbViePreclinical
Comtan
Orion Corporation, Orion PharmaPreclinical
Inversine
TTargacept Inc.
Preclinical
Permax
VValeant Pharmaceuticals
Preclinical
Catapres
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Schizophrenia5 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NBI-1117568. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company